VHL Gene Detection for PD-1/PD-L1 Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PD-1/PD-L1 targeting agents for cancer treatment have limited antitumor response rates and are expensive, with adverse reactions, necessitating the identification of predictive biomarkers for patient selection to improve therapeutic efficacy.
Innovation Solution
An in vitro or ex vivo method detects the loss of function of the von Hippel-Lindau (VHL) gene in tumor cells to predict responsiveness to PD-1/PD-L1 targeting agents, specifically using PD-1 or PD-L1 antagonists like Nivolumab, Pembrolizumab, and Atezolizumab for patients with VHL gene alterations, particularly in clear cell renal cell carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 targeting agents are used for cancer treatment, then antitumor activity is enhanced, but the response rate remains limited and costs are high
Solution Approach 1:
The patent applies preliminary action by detecting VHL gene loss of function status before initiating PD-1/PD-L1 targeting therapy. This predictive biomarker assessment allows clinicians to pre-identify patients most likely to respond to treatment, thereby improving the overall response rate and avoiding unnecessary treatment costs for patients who would not benefit.
Solution Approach 2:
The invention enables self-service by using the patient's own tumor tissue to detect VHL gene status. The method utilizes readily available clinical samples (tumor biopsies) to generate predictive information, eliminating the need for external or complex diagnostic systems while providing cost-effective patient selection.
2Strength
If PD-1/PD-L1 targeting agents are administered, then T-cell response is enhanced, but adverse reactions occur
Solution Approach 1:
The patent applies preliminary action by assessing VHL gene status before treatment to identify patients with high likelihood of response. This allows for targeted therapy administration only to suitable candidates, thereby enhancing T-cell response in responders while minimizing adverse reactions in non-responders who would not benefit from the immunotherapeutic mechanism.
3Ease of operation
If patient selection is performed without predictive biomarkers, then treatment accessibility is maintained, but therapeutic efficacy is reduced
Solution Approach 1:
The invention enables self-service by using the patient's own tumor tissue to detect VHL gene status. This approach maintains ease of operation because it utilizes readily available clinical samples that are already collected during standard diagnostic procedures, while simultaneously improving therapeutic efficacy through accurate patient selection based on predictive biomarker status.
Data Source
Figure 1A~1C
Figure 2A~2E
Figure 3A~3C
AI summary
The present invention relates to a method for assessing the response of a patient to a treatment with anti-PD-1/PDL-1 drugs based on the status of the VHL gene (von Hippel-Lindau).